# Vlad Ratziu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vlad-ratziu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 64,794 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 108 |
| i10-index | 310 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5072395263 |
| ORCID iD | 0000-0002-6865-3791 |
| Works | 688 |

## Researcher papers

Showing 12 of 24.

- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease](https://scholariq.org/papers/sampling-variability-of-liver-biopsy-in-nonalcoholic-fatty-liver-disease/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis](https://scholariq.org/papers/a-placebo-controlled-trial-of-subcutaneous-semaglutide-in-nonalcoholic/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [Viral hepatitis B](https://scholariq.org/papers/viral-hepatitis-b/)
- [Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study](https://scholariq.org/papers/biochemical-markers-of-liver-fibrosis-in-patients-with-hepatitis-c-virus/)
- [NASH limits anti-tumour surveillance in immunotherapy-treated HCC](https://scholariq.org/papers/nash-limits-anti-tumour-surveillance-in-immunotherapy-treated-hcc/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.